Cargando…

Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab

COVID-19 is characterized by a severe pulmonary disease due to severe acute respiratory syndrome (SARS)-CoV-2 infection. For clinicians involved in the management of patients with chronic autoimmune diseases the risk linked to the conditions itself and to drug-induced immunosuppression during the CO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinagra, Jo Linda, Vedovelli, Claudio, Binazzi, Raffaella, Salemme, Adele, Moro, Francesco, Mazzanti, Cinzia, Didona, Biagio, Di Zenzo, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087171/ https://www.ncbi.nlm.nih.gov/pubmed/33936104 http://dx.doi.org/10.3389/fimmu.2021.665522

Ejemplares similares

Bullous Pemphigoid: Trigger and Predisposing Factors
por: Moro, Francesco, et al.
Publicado: (2020)

Pemphigus Vulgaris: Present and Future Therapeutic Strategies
por: Didona, Dario, et al.
Publicado: (2022)

Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis
por: Didona, Dario, et al.
Publicado: (2020)

Case report: A rare case of imiquimod-induced atypical pemphigus vulgaris
por: Moro, Francesco, et al.
Publicado: (2022)

Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine
por: Pira, Anna, et al.
Publicado: (2023)

Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012)

Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 Pandemic
por: Corrà, Alberto, et al.
Publicado: (2021)

Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy
por: Paolino, Giovanni, et al.
Publicado: (2017)

Pemphigus: Current and Future Therapeutic Strategies
por: Didona, Dario, et al.
Publicado: (2019)

Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis
por: Moro, Francesco, et al.
Publicado: (2022)

Rituximab therapy improves recalcitrant Pemphigus vulgaris
por: Noormohammadpour, Pedram, et al.
Publicado: (2015)

Rituximab in Pemphigus: Road Covered and Challenges Ahead
por: Vinay, Keshavamurthy, et al.
Publicado: (2018)

Cerebral toxoplasmosis after rituximab for pemphigus vulgaris
por: Lee, Erica B., et al.
Publicado: (2019)

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians
por: Kanokrungsee, Silada, et al.
Publicado: (2021)

Paraneoplastic Pemphigus Presenting as Mild Cutaneous Features of Pemphigus Foliaceus and Lichenoid Stomatitis with Antidesmoglein 1 Antibodies
por: Niimi, Yayoi, et al.
Publicado: (2010)

AZD-1222/rituximab: Pemphigus vulgaris and pemphigus vulgaris flare-up: 2 case reports
Publicado: (2022)

Off-label use of rituximab in dermatology: pemphigus treatment
por: Bomm, Lislaine, et al.
Publicado: (2013)

Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil
por: Biot, Stephanie Del Rio Navarrete, et al.
Publicado: (2014)

Rituximab therapy in pemphigus and other autoantibody-mediated diseases
por: Ran, Nina A., et al.
Publicado: (2017)

Follow-up Data of Rituximab as Adjuvant Therapy in Pemphigus
por: Khopkar, Uday S, et al.
Publicado: (2017)

Efficacy of rituximab in pediatric pemphigus: A literature review
por: Patel, Meera H., et al.
Publicado: (2021)

Rituximab: Aggressive course of pemphigus vulgaris: case report
Publicado: (2021)

Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris
por: BAUM, Sharon, et al.
Publicado: (2020)

Successful Treatment of Recalcitrant Pediatric Pemphigus Vulgaris With Rituximab
por: Santiago-Vázquez, Marely, et al.
Publicado: (2022)

Humoral Epitope Spreading in Autoimmune Bullous Diseases
por: Didona, Dario, et al.
Publicado: (2018)

Real world evidence: Patients with refractory pemphigus treated with Rituximab
por: Perifani, Vagiani, et al.
Publicado: (2021)

Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
por: Benesh, Gabrielle, et al.
Publicado: (2021)

Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability
por: Ciolfi, Christian, et al.
Publicado: (2022)

Thrombotic Storm Induced by Rituximab in a Patient With Pemphigus Vulgaris
por: Karan, Abhinav, et al.
Publicado: (2023)

156 COVID-19 vaccine is a risk factor accelerating time to bullous pemphigoid onset
por: Pira, A., et al.
Publicado: (2023)

Identification of a Novel Non-desmoglein Autoantigen in Pemphigus Vulgaris
por: Di Lullo, Giulia, et al.
Publicado: (2019)

Brain Abscess following Rituximab Infusion in a Patient with Pemphigus Vulgaris
por: Al-Harbi, Talal M., et al.
Publicado: (2015)

Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab
por: Waldman, Reid A., et al.
Publicado: (2021)

The positive impact of rituximab on the quality of life and mental health in patients with pemphigus
por: Rashid, Hanan, et al.
Publicado: (2022)

IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
por: Font, Guillaume, et al.
Publicado: (2022)

Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy
por: Dehghanimahmoudabadi, Azin, et al.
Publicado: (2022)

Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology
por: Khandelwal, Krishna, et al.
Publicado: (2023)

SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris
por: Fenizia, Claudio, et al.
Publicado: (2023)

Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients
por: Song, Ahreum, et al.
Publicado: (2022)

Redox Enzymes of the Thioredoxin Family as Potential and Novel Markers in Pemphigus
por: Sliwiak, P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mdo7vdju66efbgbvjocm5hkhd7